Concepedia

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Pier Ferruccio Ballerini, Emilio Iannitto, Filippo Russo, Ferdinando Frigeri, Cristina Becchimanzi, Gianpaolo Marcacci, Annarosaria De Chiara,

Cancer Chemotherapy and Pharmacology · 2009 · 76 citations · 36 references

DOI

Concepts

References

36

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples

Richard Peto, M. C. Pike, P. Armitage et al. · British Journal of Cancer · 1977 · 8.4K citations · Full text

, , +13

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Nancy L. Harris, Elaine S. Jaffe, J Diébold et al. · Journal of Clinical Oncology · 1999 · 3.3K citations

, , +17

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

, , +7

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

William Plunkett, Peng Huang, Yi-Zheng Xu et al. · PubMed · 1995 · 756 citations

, , +6

Cellular and molecular pharmacology of oxaliplatin.

Éric Raymond, Sandrine Faivre, Stephen G. Chaney et al. · PubMed · 2002 · 467 citations

, , +17